Home-based exercise plus medication for people newly diagnosed with pulmonary arterial hypertension
Official title: Randomised Controlled Trial of Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension
Run by Golden Jubilee National Hospital · NCT07366879 · Data updated 2026-11-12
This trial will try a 12-week home-based, remotely supervised exercise program added to usual medication for adults newly diagnosed with pulmonary arterial hypertension to see if it improves fitness, quality of life, and mental wellbeing.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Golden Jubilee National Hospital Government |
| Locations | 1 site (Glasgow) |
| Status | Recruiting |
| Started | April 2, 2026 |
| Main results expected | August 2027 |
| Study ends | January 2028 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT07366879 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) newly diagnosed with group I pulmonary arterial hypertension or non-operable group IV confirmed by right heart catheterisation, able to consent and judged safe to perform home exercise are ideal candidates.
✕Probably not a fit
Patients with pulmonary hypertension due to left heart disease, hypoxic lung disease, operable chronic thromboembolic disease, multifactorial causes, those with exercise-related syncope, or those unable to safely exercise or already starting investigational medications are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, waitlist-controlled trial enrolls adults newly diagnosed with pulmonary arterial hypertension from the Scottish Pulmonary Vascular Unit. After starting standard pulmonary vasodilator therapy and a three-month clinic review, participants are randomized to a 12-week home-based, remotely supervised exercise program or to a control (delayed access) group. After completing the exercise program, participants are further randomized to receive an additional support package or not to test long-term adherence. Primary outcomes include change in six-minute walk distance, quality of life and mental health scores, and adherence to exercise.
Why it matters
Potential benefit: If successful, the program could increase walking distance, improve quality of life and mental health, and help people keep exercising long-term.
How similar studies have gone: Previous supervised exercise programs in PAH have shown improved six-minute walk distance and quality of life, but early, remotely supervised home programs and adherence-support packages are less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18-years-old and above * Diagnosed with pulmonary hypertension (group I and non-operable group IV) by right heart catheterisation showing: * a baseline mean pulmonary artery pressure \>20mmHg * pulmonary vascular resistance \>2 Wood Units * pulmonary capillary wedge pressure \<15mmHg * Able to provide written informed consent Exclusion Criteria: * Diagnosis with pulmonary hypertension of any other cause * Group II (PH due to left heart disease) * Group III (PH due to hypoxic lung disease) * Operable group IV (PH due to chronic thromboembolic disease amenable to surgical treatment) * Group V (unclear and/or multifactorial elements). * Planned treatment with a research trial medication during the study timeframe * Consenting clinician and/or patient concern regarding the patient's safety in performing a home-based exercise programme * Patients with syncopal episodes felt to be related to pulmonary hypertension at time of exercise intervention initiation. * Severe concurrent medical condition that would prevent participation in study procedures * Life expectancy \<3 months
Where it's running
-
Golden Jubilee National Hospital
Glasgow, United Kingdom Recruiting
Study contacts
- Study coordinator: Jamie Ingram, MBChB
- Email: jamie.ingram2@nhs.scot
- Phone: 0044 141-951-5440
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding how low-load leg exercises affect muscle and blood flow in PAH patients
This substudy tests whether a gentle leg exercise program can change blood flow and oxygen use in the calf muscles of adults with pulmonary arterial hypertension.
-
Sotatercept in Japanese children with pulmonary arterial hypertension
This study tests whether sotatercept is safe and well tolerated in Japanese children with PAH when added to standard PAH treatment.
-
DIAG723 in Adults With HHT
A first-in-human study tests DIAG723 versus placebo in adults with hereditary hemorrhagic telangiectasia to see if it is safe and possibly helpful.
-
See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease
Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.
-
Sotatercept in Indian adults with pulmonary arterial hypertension on standard therapy
This study tests whether adding sotatercept to current PAH medicines is safe and tolerable for adults with PAH in India.
-
Once-daily treprostinil palmitil inhalation powder for PAH
This study tests whether taking a daily inhaled treprostinil palmitil powder for 24 weeks improves exercise ability in adults with pulmonary arterial hypertension compared to a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.